CRMDCorMedix Inc.

$536M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8,191-50.2% YoY

Gross Profit

-$6,235-76.1% margin

Operating Income

-$6M-71813.3% margin

Net Income

-$5M-56561.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-90.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$81M

Total Liabilities

$4M

Stockholders' Equity

$77M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8,191	$16,443	-50.2%
Gross Profit	-$6,235	-$2,741	-127.5%
Operating Income	-$6M	-$9M	+34.1%
Net Income	-$5M	-$4M	-22.5%

CRMD Q2 2021 Earnings — CorMedix Inc. Revenue & Financial Results | Market Cap Arena